Markus Hecker
Corporate Officer/Principal at Ruprecht-Karls-Universität Heidelberg
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Erich Schlick | M | 72 |
Ruprecht-Karls-Universität Heidelberg
| - |
| Ernst Biekert | M | 99 |
Ruprecht-Karls-Universität Heidelberg
| 56 years |
| Mohsen M. Sohi | M | 65 |
Ruprecht-Karls-Universität Heidelberg
| - |
| Uwe Bicker | M | 79 |
Ruprecht-Karls-Universität Heidelberg
| 13 years |
| Thorlef Spickschen | M | 83 |
Ruprecht-Karls-Universität Heidelberg
| - |
| Paul Kirchhof | M | - |
Ruprecht-Karls-Universität Heidelberg
| - |
| Margret Suckale | F | 68 |
Ruprecht-Karls-Universität Heidelberg
| - |
| Malte Bahner | M | 61 |
Ruprecht-Karls-Universität Heidelberg
| - |
| Magnus von Knebel Döberitz | M | - |
Ruprecht-Karls-Universität Heidelberg
| - |
| Michael Heinz | M | 60 |
Ruprecht-Karls-Universität Heidelberg
| 7 years |
| Götz M. Richter | M | - |
Ruprecht-Karls-Universität Heidelberg
| - |
| Eugen Leo | M | - |
Ruprecht-Karls-Universität Heidelberg
| - |
| Andreas Wentzensen | M | - |
Ruprecht-Karls-Universität Heidelberg
| - |
| Gerd Auffarth | M | 59 |
Ruprecht-Karls-Universität Heidelberg
| 13 years |
| Paul Scigalla | M | 79 |
Ruprecht-Karls-Universität Heidelberg
| 32 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Christian Meyer | M | 53 |
University of Gottingen
| 12 years |
| Kristin Neumann | M | 52 |
University of Gottingen
| 5 years |
| Ahmad Erani Yustika | M | 51 |
University of Gottingen
| 5 years |
| Chang-Kyu Oh | M | - |
University of Gottingen
| 3 years |
| Kristian Reich | M | 58 |
University of Gottingen
| 3 years |
| Hans Peter Trampe | M | 61 |
University of Gottingen
| 6 years |
| Jeannette Härtling | F | 42 |
University of Gottingen
| 7 years |
| Gleb Kozyritskiy | M | - |
University of Gottingen
| 3 years |
| Wan Lei Shao | M | 56 |
University of Gottingen
| 4 years |
| Jeannette Härtling | F | - |
University of Gottingen
| 4 years |
| Kai Nikolaizig | M | - |
University of Gottingen
| 4 years |
| Jung Yang Shao | M | 43 |
University of Gottingen
| 4 years |
| Katharina Wesenick | F | 47 |
University of Gottingen
| 5 years |
| Ritika Mahal | F | - |
University of Gottingen
| 2 years |
| Marcus Johannes Chromik | M | 52 |
University of Gottingen
| 6 years |
| Anja Glisovic | M | - |
University of Gottingen
| 3 years |
| Heiko von der Leyen | M | - |
Avontec GmbH
 Avontec GmbH Pharmaceuticals: MajorHealth Technology Avontec is a Phase 2 biopharmaceutical company focused on the development and commercialization of novel therapeutic treatments for inflammatory disease. Its clinical development programs include product candidates for multiple potential inflammatory indications. The two most advanced, AVT-01 in asthma and AVT-02 in psoriasis, have successfully advanced into Phase 2a clinical trials that the firm expects to be completed until the first half of 2008. In addition, there are several candidates in the pipeline based on Avontec's core decoy technology. Avontec operates based on a lean business model with a seasoned management team experienced in clinical development. | 1 years |
| Jackie Dao | F | - |
University of Gottingen
| 1 years |
| Alexander Schinzing | M | 51 |
University of Gottingen
| 3 years |
| Jeannette Chiarlitti | F | 42 |
University of Gottingen
| 7 years |
| Chao She Guo | M | - |
University of Gottingen
| 3 years |
| Barbara Ooms-Gnauck | M | 66 |
University of Gottingen
| 3 years |
| Ernst-Günter Afting | M | 80 |
Avontec GmbH
Avontec GmbH Pharmaceuticals: MajorHealth Technology Avontec is a Phase 2 biopharmaceutical company focused on the development and commercialization of novel therapeutic treatments for inflammatory disease. Its clinical development programs include product candidates for multiple potential inflammatory indications. The two most advanced, AVT-01 in asthma and AVT-02 in psoriasis, have successfully advanced into Phase 2a clinical trials that the firm expects to be completed until the first half of 2008. In addition, there are several candidates in the pipeline based on Avontec's core decoy technology. Avontec operates based on a lean business model with a seasoned management team experienced in clinical development. | - |
| Hardy Brennecke | M | 50 |
University of Gottingen
| 4 years |
| Stefan Keveloh | M | - |
Avontec GmbH
Avontec GmbH Pharmaceuticals: MajorHealth Technology Avontec is a Phase 2 biopharmaceutical company focused on the development and commercialization of novel therapeutic treatments for inflammatory disease. Its clinical development programs include product candidates for multiple potential inflammatory indications. The two most advanced, AVT-01 in asthma and AVT-02 in psoriasis, have successfully advanced into Phase 2a clinical trials that the firm expects to be completed until the first half of 2008. In addition, there are several candidates in the pipeline based on Avontec's core decoy technology. Avontec operates based on a lean business model with a seasoned management team experienced in clinical development. | - |
| Thomas Schulze | M | 61 |
Avontec GmbH
Avontec GmbH Pharmaceuticals: MajorHealth Technology Avontec is a Phase 2 biopharmaceutical company focused on the development and commercialization of novel therapeutic treatments for inflammatory disease. Its clinical development programs include product candidates for multiple potential inflammatory indications. The two most advanced, AVT-01 in asthma and AVT-02 in psoriasis, have successfully advanced into Phase 2a clinical trials that the firm expects to be completed until the first half of 2008. In addition, there are several candidates in the pipeline based on Avontec's core decoy technology. Avontec operates based on a lean business model with a seasoned management team experienced in clinical development. | 7 years |
| Jürgen Gerlach | M | - |
Avontec GmbH
Avontec GmbH Pharmaceuticals: MajorHealth Technology Avontec is a Phase 2 biopharmaceutical company focused on the development and commercialization of novel therapeutic treatments for inflammatory disease. Its clinical development programs include product candidates for multiple potential inflammatory indications. The two most advanced, AVT-01 in asthma and AVT-02 in psoriasis, have successfully advanced into Phase 2a clinical trials that the firm expects to be completed until the first half of 2008. In addition, there are several candidates in the pipeline based on Avontec's core decoy technology. Avontec operates based on a lean business model with a seasoned management team experienced in clinical development. | - |
| Wolfgang Barth | M | - |
Avontec GmbH
Avontec GmbH Pharmaceuticals: MajorHealth Technology Avontec is a Phase 2 biopharmaceutical company focused on the development and commercialization of novel therapeutic treatments for inflammatory disease. Its clinical development programs include product candidates for multiple potential inflammatory indications. The two most advanced, AVT-01 in asthma and AVT-02 in psoriasis, have successfully advanced into Phase 2a clinical trials that the firm expects to be completed until the first half of 2008. In addition, there are several candidates in the pipeline based on Avontec's core decoy technology. Avontec operates based on a lean business model with a seasoned management team experienced in clinical development. | 4 years |
| Stefan W. Henning | M | - |
Avontec GmbH
Avontec GmbH Pharmaceuticals: MajorHealth Technology Avontec is a Phase 2 biopharmaceutical company focused on the development and commercialization of novel therapeutic treatments for inflammatory disease. Its clinical development programs include product candidates for multiple potential inflammatory indications. The two most advanced, AVT-01 in asthma and AVT-02 in psoriasis, have successfully advanced into Phase 2a clinical trials that the firm expects to be completed until the first half of 2008. In addition, there are several candidates in the pipeline based on Avontec's core decoy technology. Avontec operates based on a lean business model with a seasoned management team experienced in clinical development. | - |
| Marc Schütt | M | - |
University of Gottingen
| 5 years |
| Thomas Fink | M | 52 |
Avontec GmbH
Avontec GmbH Pharmaceuticals: MajorHealth Technology Avontec is a Phase 2 biopharmaceutical company focused on the development and commercialization of novel therapeutic treatments for inflammatory disease. Its clinical development programs include product candidates for multiple potential inflammatory indications. The two most advanced, AVT-01 in asthma and AVT-02 in psoriasis, have successfully advanced into Phase 2a clinical trials that the firm expects to be completed until the first half of 2008. In addition, there are several candidates in the pipeline based on Avontec's core decoy technology. Avontec operates based on a lean business model with a seasoned management team experienced in clinical development. | 5 years |
| Michael Hecker | M | 54 |
University of Gottingen
| 3 years |
| Lee-Cheng Liu | M | - |
Avontec GmbH
Avontec GmbH Pharmaceuticals: MajorHealth Technology Avontec is a Phase 2 biopharmaceutical company focused on the development and commercialization of novel therapeutic treatments for inflammatory disease. Its clinical development programs include product candidates for multiple potential inflammatory indications. The two most advanced, AVT-01 in asthma and AVT-02 in psoriasis, have successfully advanced into Phase 2a clinical trials that the firm expects to be completed until the first half of 2008. In addition, there are several candidates in the pipeline based on Avontec's core decoy technology. Avontec operates based on a lean business model with a seasoned management team experienced in clinical development. | - |
| Markus Hosang | M | - |
Avontec GmbH
Avontec GmbH Pharmaceuticals: MajorHealth Technology Avontec is a Phase 2 biopharmaceutical company focused on the development and commercialization of novel therapeutic treatments for inflammatory disease. Its clinical development programs include product candidates for multiple potential inflammatory indications. The two most advanced, AVT-01 in asthma and AVT-02 in psoriasis, have successfully advanced into Phase 2a clinical trials that the firm expects to be completed until the first half of 2008. In addition, there are several candidates in the pipeline based on Avontec's core decoy technology. Avontec operates based on a lean business model with a seasoned management team experienced in clinical development. | - |
| Miki Nakamori | F | - |
Avontec GmbH
Avontec GmbH Pharmaceuticals: MajorHealth Technology Avontec is a Phase 2 biopharmaceutical company focused on the development and commercialization of novel therapeutic treatments for inflammatory disease. Its clinical development programs include product candidates for multiple potential inflammatory indications. The two most advanced, AVT-01 in asthma and AVT-02 in psoriasis, have successfully advanced into Phase 2a clinical trials that the firm expects to be completed until the first half of 2008. In addition, there are several candidates in the pipeline based on Avontec's core decoy technology. Avontec operates based on a lean business model with a seasoned management team experienced in clinical development. | - |
| Alexandra Krieger | F | 53 |
University of Gottingen
| 8 years |
| Joerg Weiser | M | 57 |
University of Gottingen
| 3 years |
| Olaf Holzkämper | M | 54 |
University of Gottingen
| 3 years |
| Frank Hennecke | M | 61 |
University of Gottingen
| 3 years |
| Jens Bitzer | M | - |
University of Gottingen
| 3 years |
| Tobias Schulz-Isenbeck | M | - |
University of Gottingen
| 3 years |
| Peter Flägel | M | - |
University of Gottingen
| 3 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| Germany | 57 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Markus Hecker
- Personal Network
